Objective Anticoagulation therapy with warfarin is associated with a favorable prognosis in ischemic stroke. Dabigatran, a new oral anticoagulant, is widely used to prevent ischemic stroke in non-valvular atrial fibrillation (NVAF) patients. However, its association with decreased severity and a favorable prognosis once ischemic stroke has occurred remains unknown. Methods We retrospectively reviewed all the patients with NVAF-associated ischemic stroke admitted to our hospital from April 2011 to December 2014 and included those who received dabigatran therapy. We assessed whether the patients were under regular use of the drug or discontinuance and classified them into 2 groups, the treatment and discontinuation groups. Clinical data, including the age, sex, ASCOD stroke phenotype, NVAF type, prescribed drug dose, comorbidities, CHADS2 score, renal function, National Institute of Health Stroke Scale (NIHSS) score on admission, modified Rankin scale (mRS) score at discharge, D-dimer, and brain natriuretic peptide, were investigated and compared between the groups. Results Nine patients were under regular dabigatran therapy, and 6 were under discontinuance of the drug. The age, sex, ASCOD stroke phenotype, NVAF type, comorbidities, renal function, and CHADS2 scores did not differ between the 2 groups; however, the NIHSS scores were significantly lower in the treatment group. The mRS scores at discharge were additionally decreased in the treatment group. Moreover, the D-dimer scores were lower in the treatment group, thus suggesting a possible role in the decreased stroke severity. Conclusion Dabigatran may therefore decrease the severity of ischemic stroke, even if ischemic stroke occurs.
Introduction
Cardioembolic stroke is the most severe subtype of ischemic stroke. Approximately half of all patients presenting with cardiogenic cerebral embolism die within 1 year of its occurrence (1) . Atrial fibrillation (AF), in particular nonvalvular AF (NVAF), is the most common cause of cardioembolic stroke (2) . Therefore, the prevention of cerebral embolism in NVAF patients is of great importance.
For a long time, warfarin has been used to prevent cardioembolic stroke in NVAF patients. Besides its preventive effect, this drug is beneficial for reducing disease severity even when ischemic stroke occurs. Previous reports showed that anticoagulation therapy with warfarin was associated with less severe neurological deficits and a favorable prognosis (3) (4) (5) .
stroke in the patients with NVAF compared with warfarin therapy (7) . Conversely, it remains unknown whether this drug has any beneficial effect in reducing the disease severity after the occurrence of ischemic stroke. We herein investigate the clinical and laboratory features of patients with ischemic stroke who were taking dabigatran. Through this study, we aim to elucidate whether NOACs have a protective effect against ischemic stroke, even after its occurrence.
Materials and Methods
This study was approved by the Institutional Review Board at Saitama Medical University International Medical Center.
When a patient with stroke is admitted to our hospital, we typically review the medication that the patient has been prescribed. When patients or family members do not bring their medication records, we contact the primary physician and obtain the drug information of the patient (current and past drug histories). Thus, in our hospital, the history of prescriptions for all patients with stroke is available. We retrospectively reviewed all the patients with ischemic stroke associated with NVAF admitted to our hospital from April 2011 to December 2014. Among these, 15 patients were prescribed dabigatran, and they were thus included in this study.
Through patient interviews or assessments of the drug records, we confirmed whether a patient was under regular use of dabigatran or discontinuation. The reason of the discontinuation varied. We divided the patients into 2 groups: a treatment group, consisting of the patients with a regular drug intake with the last medication administered within 12 hours, and a discontinuation group, consisting of the patients who were discontinuing the drug treatment. Discontinuation was defined as those who suspended the drug for more than 24 hours, however, all the patients in this group had stopped the drug for more than 5 days (discussed later). None of the patients used warfarin or other NOACs simultaneously. The age, sex, prescribed drug dose, discontinued period (only for the discontinuation group), NVAF type (i.e., paroxysmal or persistent), comorbidities (e.g., heart failure, hypertension, diabetes mellitus, and past history of stroke), CHADS2 score, creatinine clearance (calculated by the CockcroftGault formula), National Institute of Health Stroke Scale (NIHSS) score on admission, modified Rankin Scale (mRS) score at discharge, serum D-dimer levels, and serum brain natriuretic peptide (BNP) were retrospectively reviewed. The patients with clinical symptom of heart failure of New York Heart Association II or worse, and/or an ejection fraction less than 50% by echocardiography, were defined as having heart failure. The patients with a blood pressure of ! 140/90 mmHg and/or those receiving antihypertensive medication were defined as having hypertension (8) . Diabetes mellitus was defined as a blood glucose level of ! 200 mg/dL and a glycated hemoglobin level of ! 6.5% on admission and/or treatment with anti-diabetic medication (8) . The initial measurements of the D-dimer and BNP levels were used in the present study. The D-dimer level was measured within 24 hours and BNP was measured within 72 hours after admission in all the patients. Furthermore, because stroke etiology other than cardioembolism may be implicated even in the patients with NVAF, we investigated the ASCOD stroke phenotypes in all patients, because such phenotyping takes all the possible stroke etiologies into consideration and is highly recommended in stroke studies (9) . The phenotypes were compared between the treatment group and discontinuation group.
Statistical analysis was performed using the PASW Statistics software program (version 18, SPSS, Chicago, USA). The age, D-dimer, and BNP differences between the groups were analyzed using the Wilcoxon test; differences in other variables were assessed using the chi-square test. For each analysis, a p value of less than 0.05 was considered to be statistically significant.
Results
There were 15 patients with NVAF-associated ischemic stroke, to whom dabigatran had been prescribed. There were no patients with transient ischemic attack; all the patients had complete strokes. Among them, 9 patients were taking dabigatran regularly, indicating that they had been taking the drug within 12 hours. Six patients, on the other hand, had discontinued the drug; 2 of these had confidentially discontinued the drug by themselves, the other 2 had suspended its use because their stools appeared blackish, 1 had tentatively stopped its use due to a scheduled colon polypectomy, and another had discontinued its use following the doctor's recommendation. The discontinuation period varied from 5 days to months (Table 1) . Due to the short half-life of dabigatran, all the patients in the discontinuation group did not have residual effects of this drug.
The demographic data, ASCOD subtype, AF type, prescribed drug dose, comorbidities, CHADS2 scores, creatinine clearance, NIHSS scores on admission, mRS scores at discharge, and the laboratory data (D-dimer and BNP) of all the patients are listed in Table 1 . We suspected that patients under regular dabigatran therapy may have had etiologies other than cardioembolism, and therefore performed ASCOD subtyping in all patients. However, the implication of atherosclerosis (A), small vessel disease (S), and other etiologies (O) did not differ among the two groups. With regard to dissection (D), 1 patient in the treatment group had a proven carotid artery dissection (case 3). The type of AF (i.e., paroxysmal or persistent) was also similar between the two groups; 4/9 in the treatment group and 2/4 in the discontinuance group had paroxysmal AF.
As shown in Table 2 , each data set was compared between the two groups. There were no differences in the age and sex between the groups. Comorbidities, such as heart failure, hypertension, diabetes mellitus, and a past history of Creatinine clearance was calculated by Cockcroft-Gault formula. BNP: brain natriuretic peptide, mRS: modified Rankin Scale, NIHSS: National Institute of Health Stroke Scale stroke (all of these are components of the CHADS2 score), as well as the renal function, did not significantly differ between the two groups. Additionally, the CHADS2 scores did not differ between the two groups. The NIHSS scores, however, showed a significant difference; the median score in the treatment group was 1, whereas that in the discontinuation group was 12.5 (p<0.05). The mRS scores at discharge was also significantly lower in the treatment group (median, 1) than in the discontinuation group (median, 4) (p=0.027).
The results of the NIHSS and mRS scores are expressed as box plots in Figure, respectively. With regard to the laboratory findings, the BNP concentration did not differ between the two groups; however, the D-dimer level was markedly lower in the treatment group, thus indicating that the thrombi tended to be larger in the discontinuation group.
Discussion
The patients with NVAF still have a risk of stroke, even if they are under anticoagulation therapy (10) . In a RE-LY trial, the annual occurrence of ischemic stroke or systemic embolism was 1.71% in the warfarin group, 1.54% in the dabigatran 110-mg b.i.d. group, and 1.11% in the dabigatran 150-mg b.i.d. group (7) . However, which patients are at the highest risk of having ischemic strokes while under anticoagulation therapy remains unclear. For the patients under warfarin therapy, insufficient anticoagulation therapy is associated with a higher stroke occurrence rate (11); thus, the status of anticoagulation should be monitored by measuring the prothrombin time-internationalized ratio (10, 12) . Conversely, for those under dabigatran therapy, the relative differences in the risks have not yet been identified. From the present study, we observed the discontinuation of dabigatran may be one of the risks. Six of the 15 (40%) patients with ischemic stroke under dabigatran therapy had discontinued the drug. However, because we do not know the frequency of the tentative suspension of dabigatran in the patients without stroke, we were unable to evaluate the risk adequately. Nevertheless, we speculate that 40% of the cases of drug discontinuation are far worse than general adherence. As described above, 3/6 patients discontinued the drug without a specific reason, and 2 stopped because their stools appeared blackish. However, when we investigated the human hemoglobin levels in these patients' stool samples, no gastrointestinal bleeding was observed. Therefore, NOACs should be discontinued only after careful consideration. A previous report revealed that the reluctance to reinitiate anticoagulation therapy after gastrointestinal bleedings was associated with a poor outcome (13) .
Even if a stroke has occurred, the regular use of dabigatran made it less severe (Table 2, Figure) . This is similar to the previously confirmed findings of warfarin treatment (3) (4) (5) . Anticoagulation therapy, either with warfarin or dabigatran, may be useful not only for preventing ischemic stroke, but also for reducing the stroke severity when it occurs. As shown in Table 1 , the patients in the discontinu- Figure. Box plots of the National Institute of Health Stroke Scale (NIHSS) scores on admission (A) and modified Rankin Scale (mRS) scores at discharge (B) in the stroke patients with NVAF. The NIHSS scores were significantly lower in the treatment group than in the discontinuation group (p<0.05). Additionally, the mRS scores were lower in the treatment group than in the discontinuation group (p=0.027). ation group had not taken dabigatran for 5 days or more. Due to the short half-life of this drug, we can presume that the patients in the discontinuation group had no residual effects of this drug.
With regard to the stroke severity-reducing effect of warfarin, several mechanisms have been postulated. Warfarin may make the thrombi smaller or more fragile (14) . The inhibition of the thrombotic system may result in predominance of the fibrinolytic system (15) . In the present study, the treatment group showed a significantly lower level of serum D-dimer than the discontinuance group (Table 2 ). This suggests that dabigatran made the causative thrombi smaller, thereby reducing the severity of the stroke.
There are other possibilities which may have affected the stroke severity and clinical outcome. Although they were not statistically significant, heart failure and decreased creatinine clearance tended to be more common in the discontinuation group (Table 1 , 2). We additionally hypothesized that the stroke etiology was entirely different in the treatment group. For instance, ischemic stroke may be caused by carotid atherothrombosis in the patients with NVAF under dabigatran therapy (16) . However, ASCOD subtyping revealed that the potential involvement of etiologies other than cardioembolism was similar in both groups, and thus the stroke severity-reducing effect of dabigatran was not a result of the differences in stroke etiology.
A previous study showed that intracranial hemorrhage in the patients under dabigatran therapy tended not to be severe (17) . In the present study, we demonstrated that ischemic stroke in the dabigatran-treated patients may be less severe than in those without regular use of the drug. There are several limitations associated with this study; the present study investigated a small number of patients and was retrospective in nature. Therefore, a prospective study with a larger number of patients would be required to confirm the present findings. Nonetheless, we speculate that the beneficial effect of anticoagulation therapy with dabigatran would be more significant than expected by the number of ischemic stroke occurrences according to the present findings.
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